This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dyax Corporation CEO Discusses Q3 2010 Results - Earnings Call Transcript

As of last Friday, October 22nd, we have 419 patients in KALBITOR access and the (inaudible) 246 patients have KALBITOR placed at the treatment site. So we more than doubled the amount of patients on KALBITOR since the last quarter and had approximately an eight-fold increase over the patients in the first quarter. At nine months into KALBITOR's loss we believed we had the large HAE patient base than any other company in the HAE market at this point in their lives. Based on these positive numbers we are reaffirming our previous guidance that we will have more than 300 hundred patients with KALBITOR placed at the treatment centers by year-end. As we've indicated before building a patient base is our number priority. With this momentum going into the fourth quarter we are well poised for future success. We believe KALBITOR's adoption in the market place can be attributed to several factors.

One of which is the growing realization among HAE patients and their physicians that they need to be prepared for their next attack. Now that there is an acute an option. It has been proven to treat all attack locations; patients understand that is possible to have a more effective treatment plan in place. Furthermore reasonable market research indicates that patients would rather treat their disease acutely and prophylactically. To that end we continue to see prophylactic patients taking KALBITOR to treat near break through attacks. Regarding KALBITOR's availability world wide we have made significant progress with our global development and commercially safe strategy, as we have shared with you in the past our objective is to partner outside the U.S. with the company's committed to developing treatments for rare diseases.

Our news collaboration in Japan we chose a partner with that level of dedication. Ivana will tell you more about this after our launch update. With respect to our financials George will provide more detail later in the call and discuss note worthy highlights for the quarter. Then Bill will update you regarding our life cycle management program for KALBITOR. This involves (inaudible) work, a potential pediatric legal expansion, and additional indications for each inhibitor induced (inaudible). Finally, I'll provide an overview of our pipeline and (inaudible) to fund research program before we conclude the call.

2 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs